Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Yashraj Biotechnology Ltd & Others Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Glorious Holdings Pvt Ltd Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vincent Commercial Co Ltd Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Allotment
In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform your good office that the Board of Directors of the Company has passed the resolution by circulation on January 07, 2021 and has approved the Allotment of 10,00,000 (Ten Lakh) equity Shares of Rs. 10/- (Rupees Ten) each for cash at a price of Rs. 30 /- (Rupees Thirty only) per share (including a premium of Rs. 20/- per share), the price has been calculated in accordance with the SEBI (ICDR) Regulations, 2018, aggregating to Rs. 3,00,00,000 /- (Rupees Three Crores) on preferential basis to Strategic Investors not forming part of Promoters Group of the Company. Aspira Pathlab & Diagnostics Ltd - 540788 - Closure of Trading Window
The financial results of the Company for the December 31, 2020 will be declared in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. With reference to the above captioned matter, we would like to inform you that pursuant to the Securities & Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's Code of Conduct for prohibition of insider trading ('Code') the trading window for dealing in securities of the Company will be closed for the purpose of declaration of Financial Results of the Company for the quarter ended December 31, 2020 for all the Designated person of the Company from Friday, January 01, 2021 and shall open 48 hours after announcement of the financial Results, for all its designated persons. Aspira Pathlab & Diagnostics Ltd - 540788 - Non-Applicability Of Related Party Transactions Under Regulation 23 (9) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ('SEBI (LODR) Regulations, 2015')
This is in reference to the captioned subject in connection with the non-applicability of Regulations 23(9) of SEBI (LODR) Regulations, 2015. We respectfully submit that as the Company falls under criteria as specified under the Regulations 15 (2) of SEBI (LODR) Regulations, 2015 and the paid up equity share capital and net worth of the Company was below Rs. 10 Crores and 25 Crores, respectively as on 31st March, 2020 and thus not required to submit the related party transaction disclosures as required under Regulation 23(9) of SEBI (LODR) Regulations, 2015 The paid up equity share capital and net worth of the Company as on 31st March, 2020 (Previous Financial Year) was Rs. 9,29,30,000/- (Rupees Nine Crores Twenty Nine Lakhs Thirty Thousand) and Rs. 3,80,08,830/- (Rupees Three Crores Eighty Lakhs Eight Thousand Eight Hundred Thirty ) respectively. Aspira Pathlab & Diagnostics Ltd - 540788 - Newspaper Advertisement Pursuant To Regulation 47 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, we are enclosing herewith the copy of Newspaper advertisement of the unaudited Financial Results for the quarter ended 30th September , 2020 published in Business Standard (English Language) and Mumbai Lakshadeep (Marathi Language) on November 11, 2020 for your reference and record. Aspira Pathlab & Diagnostics Ltd - 540788 - Unaudited Financial Results For The Quarter Ended September 30, 2020
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we enclose a copy of the statements containing the unaudited Financial Results of the Company for the quarter ended September 30, 2020, which has been approved at the meeting of the Board of Directors held today. We also enclose a copy of the Limited Review Report for the quarter ended September 30, 2020 issued by Statutory Auditors. The Board Meeting commenced at 3.00 pm and concluded at 5 pm. Aspira Pathlab & Diagnostics Ltd - 540788 - Outcome Of Meeting Of The Board Of Directors Held On November 10, 2020, Pursuant To Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is to inform you that the Board of Directors of the Company, at their meeting held today at 3 p.m. has, inter alia, considered and approved the un-audited financial results of the Company for the quarter ended September 30, 2020. A copy of Unaudited Financial Results and Limited Review Report as received from Statutory Auditors is enclosed for your information and record. The meeting of the Board of Directors concluded at 5 p.m. Aspira Pathlab & Diagnostics Ltd - 540788 - Compliance Under Regulation 47 Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed Public Notice published in the Newspapers viz.- Business Standard (in English) and Mumbai Lakshdeep (in Marathi), informing about the Board Meeting scheduled to be held on November 10, 2020 to, inter alia, consider and approve the Unaudited Financial Results of the Company for the Quarter ended September 30, 2020.